Altimmune (id:6652 ALT)
8.68 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 10:57:30 PM)
Exchange closed, opens in 1 day 10 hours
About Altimmune
Market Capitalization 508.54M
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
| Headquarters (address) |
910 Clopper Road Gaithersburg 20878 MD United States |
| Phone | 240 654 1450 |
| Website | https://altimmune.com |
| Employees | 59 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | ALT |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 2.76 - 14.84 |
| Market Capitalization | 508.54M |
| Dividend yield forward | 134.10 % |
| Dividend yield forward United States (ID:6, base:1864) | 4.13 % |
| P/E trailing | -5.23 |
| P/E forward | -4.86 |
| Price/Sale | 9,779.63 |
| Price/Book | 3.81 |
| Beta | 0.072 |
| EPS | -1.63 |
| EPS United States (ID:6, base:3403) | 24.22 |
Forward Annual Dividend Yield
Forward Annual Dividend Yield: Altimmune has raised their dividend 134.10 years in a row. This is below the 41473.299300 year average in the 'Biotechnology' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: Altimmune has raised their dividend 134.10 years in a row. This is below the 41473.299300 year average in the 'Biotechnology' industry